Yue Tao1,2, Fabienne Heskia3, Mingjie Zhang4, Rong Qin3, Bin Kang1,5, Luoquan Chen1,5, Fei Wu1,5, Jihong Huang4, Karen Brengel-Pesce6, Huiwen Chen4, Xi Mo1,2, Ji Liang1,5, Wei Wang4, Zhuoming Xu7. 1. Shanghai Children's Medical Center-bioMérieux Laboratory, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. 2. The Laboratory of Pediatric Infectious Diseases, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. 3. Global Medical Affairs Department, bioMérieux SA, Marcy l'Etoile, France. 4. Department of Thoracic and Cardiovascular Surgery, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. 5. bioMérieux (Shanghai) Company Limited, Shanghai, China. 6. Open Innovation & Partnerships Department, bioMérieux SA, Marcy l'Etoile, France. 7. Department of Thoracic and Cardiovascular Surgery, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. zmxcicu@163.com.
Abstract
BACKGROUND: With adult patients, the measurement of [TIMP-2]*[IGFBP7] can predict the risk of moderate to severe AKI within 12 h of testing. In pediatrics, however, the performance of [TIMP-2]*[IGFBP7] as a predictor of AKI was less studied and yet to be widely utilized in clinical practice. This study was conducted to validate the utility of [TIMP-2]*[IGFBP7] as an earlier biomarker for AKI prediction in Chinese infants and small children. METHODS: We measured urinary [TIMP-2]*[IGFBP7] using NEPHROCHECK® at eight perioperative time points in 230 patients undergoing complex cardiac surgery and evaluated the performance of [TIMP-2]*[IGFBP7] for predicting severe AKI within 72 h of surgery. RESULTS: A total of 50 (22%) of 230 developed AKI stages 2-3 within 72 h after CPB initiation. In the AKI stage 2-3 patients, two patterns of serum creatinine (SCr) elevations were observed. The patients with only a transient increase in SCr within 24 h (< 24 h, early AKI 2-3) did not experience a worse outcome than patients in AKI stage 0-1. AKI stage 2-3 patients with SCr elevation after 24 h (24-72 h, late AKI 2-3), as well as AKI dialysis patients (together designated severe AKI), did experience worse outcomes. Compared to AKI stages 0-1, significant elevations of [TIMP-2]*[IGFBP7] values were observed in severe AKI patients at hours T2, T4, T12, and T24 following CPB initiation. The AUC for predicting severe AKI with [TIMP-2]*[IGFBP7] at T2 (AUC = 0.76) and maximum T2/T24 (AUC = 0.80) are higher than other time points. The addition of the NEPHROCHECK® test to the postoperative parameters improved the risk assessment of severe AKI. CONCLUSIONS: Multiple AKI phenotypes (early versus late AKI) were identified after pediatric complex cardiac surgery according to SCr-based AKI definition. Urinary [TIMP-2]*[IGFBP7] predicts late severe AKI (but not early AKI) as early as 2 h following CPB initiation. A higher resolution version of the Graphical abstract is available as Supplementary information.
BACKGROUND: With adult patients, the measurement of [TIMP-2]*[IGFBP7] can predict the risk of moderate to severe AKI within 12 h of testing. In pediatrics, however, the performance of [TIMP-2]*[IGFBP7] as a predictor of AKI was less studied and yet to be widely utilized in clinical practice. This study was conducted to validate the utility of [TIMP-2]*[IGFBP7] as an earlier biomarker for AKI prediction in Chinese infants and small children. METHODS: We measured urinary [TIMP-2]*[IGFBP7] using NEPHROCHECK® at eight perioperative time points in 230 patients undergoing complex cardiac surgery and evaluated the performance of [TIMP-2]*[IGFBP7] for predicting severe AKI within 72 h of surgery. RESULTS: A total of 50 (22%) of 230 developed AKI stages 2-3 within 72 h after CPB initiation. In the AKI stage 2-3 patients, two patterns of serum creatinine (SCr) elevations were observed. The patients with only a transient increase in SCr within 24 h (< 24 h, early AKI 2-3) did not experience a worse outcome than patients in AKI stage 0-1. AKI stage 2-3 patients with SCr elevation after 24 h (24-72 h, late AKI 2-3), as well as AKI dialysis patients (together designated severe AKI), did experience worse outcomes. Compared to AKI stages 0-1, significant elevations of [TIMP-2]*[IGFBP7] values were observed in severe AKI patients at hours T2, T4, T12, and T24 following CPB initiation. The AUC for predicting severe AKI with [TIMP-2]*[IGFBP7] at T2 (AUC = 0.76) and maximum T2/T24 (AUC = 0.80) are higher than other time points. The addition of the NEPHROCHECK® test to the postoperative parameters improved the risk assessment of severe AKI. CONCLUSIONS: Multiple AKI phenotypes (early versus late AKI) were identified after pediatric complex cardiac surgery according to SCr-based AKI definition. Urinary [TIMP-2]*[IGFBP7] predicts late severe AKI (but not early AKI) as early as 2 h following CPB initiation. A higher resolution version of the Graphical abstract is available as Supplementary information.
Authors: Pierre Delanaye; Christophe Mariat; Etienne Cavalier; Nicolas Maillard; Jean-Marie Krzesinski; Christine A White Journal: Nephron Clin Pract Date: 2011-08-11
Authors: Rajit K Basu; Hector R Wong; Catherine D Krawczeski; Derek S Wheeler; Peter B Manning; Lakhmir S Chawla; Prasad Devarajan; Stuart L Goldstein Journal: J Am Coll Cardiol Date: 2014-12-30 Impact factor: 24.094
Authors: Kathleen D Liu; B Taylor Thompson; Marek Ancukiewicz; Jay S Steingrub; Ivor S Douglas; Michael A Matthay; Patrick Wright; Michael W Peterson; Peter Rock; Robert C Hyzy; Antonio Anzueto; Jonathon D Truwit Journal: Crit Care Med Date: 2011-12 Impact factor: 7.598
Authors: Scott I Aydin; Howard S Seiden; Andrew D Blaufox; Vincent A Parnell; Tarif Choudhury; Ann Punnoose; James Schneider Journal: Ann Thorac Surg Date: 2012-08-09 Impact factor: 4.330
Authors: Jeffrey A Alten; David S Cooper; Joshua J Blinder; David T Selewski; Sarah Tabbutt; Jun Sasaki; Michael G Gaies; Rebecca A Bertrandt; Andrew H Smith; Garrett Reichle; Katja M Gist; Mousumi Banerjee; Wenying Zhang; Kristal M Hock; Santiago Borasino Journal: Crit Care Med Date: 2021-10-01 Impact factor: 9.296